# Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2

David C. Hoaglin, PhD[1],*, Neil Hawkins, PhD[2], Jeroen P. Jansen, PhD[3], David A. Scott, MA[2], Robbin Itzler, PhD[4], Joseph C. Cappelleri, PhD, MPH[5], Cornelis Boersma, PhD, MSc[6], David Thompson, PhD[7], Kay M. Larholt, ScD[8], Mireya Diaz, PhD[9], Annabel Barrett[10]

[1]Independent consultant, Sudbury, MA, USA; [2]Oxford Outcomes Ltd., Oxford, UK; [3]Mapi Values, Boston, MA, USA; [4]Merck Research Laboratories, North Wales, PA, USA; [5]Pfizer Inc., New London, CT, USA; [6]University of Groningen/HECTA, Groningen, The Netherlands; [7]i3 Innovus, Medford, MA, USA; [8]HealthCore, Inc., Andover, MA, USA; [9]Henry Ford Health System, Detroit, MI, USA; [10]Eli Lilly and Company Ltd., Windlesham, Surrey, UK

A B S T R A C T

Evidence-based health care decision making requires comparison of all relevant competing interventions. In the absence of randomized controlled trials involving a direct comparison of all treatments of interest, indirect treatment comparisons and network meta-analysis provide useful evidence for judiciously selecting the best treatment(s). Mixed treatment comparisons, a special case of network meta-analysis, combine direct evidence and indirect evidence for particular pairwise comparisons, thereby synthesizing a greater share of the available evidence than traditional meta-analysis. This report from the International Society for Pharmacoeconomics and Outcomes Research Indirect Treatment Comparisons Good Research Practices Task Force provides guidance on technical aspects of conducting network meta-analyses (our use of this term includes most methods that involve meta-analysis in the context of a network of

evidence). We start with a discussion of strategies for developing networks of evidence. Next we briefly review assumptions of network meta-analysis. Then we focus on the statistical analysis of the data: objectives, models (fixed-effects and random-effects), frequentist versus Bayesian approaches, and model validation. A checklist highlights key components of network meta-analysis, and substantial examples illustrate indirect treatment comparisons (both frequentist and Bayesian approaches) and network meta-analysis. A further section discusses eight key areas for future research.

*Keywords:* Bayesian meta-analysis, direct treatment comparison, evidence network, frequentist meta-analysis, heterogeneity, inconsistency, indirect treatment comparison, mixed treatment comparison.

Copyright © 2011, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.

## Background to the task force

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Board of Directors approved the formation of an Indirect Treatment Comparisons Good Research Practices Task Force to develop good research practices document(s) for indirect treatment comparisons in January 2009. Researchers, experienced in systematic reviews, network meta-analysis, synthesis of evidence, and related statistical methods, working in academia, research organizations, the pharmaceutical industry, or government, from the United States, Canada, and Europe were invited to join the Task Force Leadership Group. Several health care decision-makers who use indirect-direct-treatment-comparison evidence in health care decisions were also invited. The Task Force met, primarily by teleconference with an ongoing exchange of email, and face to-face in April 2010, to develop the topics to be addressed, agree on the outline, and draft the report. The Leadership Group determined that, to adequately address good research practices for indirect treatment comparisons and the use of these comparisons in health care

decisions, the Task Force Report would comprise two articles, "Interpreting Indirect Treatment Comparisons & Network Meta-Analysis for Health Care Decision-Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1" and "Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2." Summaries were presented for comment at the 15th Annual International Meeting in Atlanta, GA, USA, in May 2010. Drafts were sent for comment to the Task Force Review Group (103 invited and self-selected individuals interested in this topic) in July 2010. The authors considered the comments from the Task Force Review Group, and the revised drafts were sent for comment to the ISPOR membership (5550) in September 2010. Altogether, Part 1 received 23 comments, and Part 2 received 13 comments. All written comments are published at the ISPOR Web site. The authors considered all comments (many of which were substantive and constructive), made revisions, and submitted them to *Value in Health*.

## Introduction

The ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices is publishing its report as two articles. This article relies on Part 1 of the report [1] for motivation, concepts, and a variety of definitions (e.g., indirect treatment comparison [ITC], mixed treatment comparison, network meta-analysis, heterogeneity, similarity, and consistency).

Terminology for indirect treatment comparisons, mixed treatment comparisons, and network meta-analysis varies in the literature. In practice, all of these methods involve meta-analysis in the context of a network of evidence. Thus it seems beneficial to use a single term for all except the simplest analyses: "network meta-analysis" applies when the evidence network involves more than two randomized controlled trials (RCTs) and more than two interventions.

Part 1 of the report emphasizes aspects of network meta-analysis that are of most importance to decision makers and others who must appreciate and apply the results of such studies. We encourage readers to study it before proceeding with this article, which focuses on more-technical aspects of conducting a network meta-analysis. The sections that follow discuss strategies for developing the network of evidence, assumptions, and statistical methods (objectives, models, frequentist vs. Bayesian approaches, and model validation). We then present a checklist for good research practices, discuss illustrative examples, and conclude by mentioning eight areas of current and needed research.

## Identifying the evidence network

A network meta-analysis starts with a network of evidence: the relevant treatments and the clinical trials that have compared those treatments directly. Its structure is often readily apparent from a diagram in which each node represents a treatment (or perhaps a class of treatments), and each link or edge connects treatments that have been directly compared in one or more RCTs. The structure of the network may have implications for the interpretation of the evidence [2]. Part 1 of the report contains diagrams for several types of evidence networks.

The literature search for a network meta-analysis builds the network, applying the same basic standards as for a meta-analysis leading to a direct comparison [3–6]. If the focus is a comparison of two treatments, say B and C, the search aims to locate all studies that have included B and another comparator, all studies that have included C and another comparator, and any studies that have compared B and C directly.

If no studies have compared B and C, but each has been compared with a common comparator, say A, then it may be appropriate to base an indirect comparison of B and C on the direct comparison of B and A and the direct comparison of C and A. Beyond this straightforward situation, B and C may have other common comparators—or none at all.

In the absence of a common comparator for B and C, the treatments with which they have been compared may have a common comparator, or the connection with a common comparator may require additional links. If more than a few links separate B and C, an indirect comparison may be unreliable, because each additional link tends to increase the standard error of the indirect comparison [7]. The contribution of a link depends on a number of factors, including the number of studies underlying that direct comparison, the sample sizes in those studies, and the homogeneity of the study-specific estimates. A decision on proceeding with an indirect comparison should, therefore, consider more information than the number of links.

It may be difficult to identify all relevant comparators for the treatments of interest, and any search involves costs and trade-

**Table 1 – The first five searches in the breadth-first strategy. Each search uses the Boolean odds ratio to combine comparators.**

| Search | Comparators |
| --- | --- |
| 1 | All primary comparators except one |
| 2 | All primary comparators |
| 3 | All secondary comparators except one |
| 4 | All secondary comparators |
| 5 | All tertiary comparators except one |

Adapted from Table 1 of Hawkins et al. [7].

offs. It may be efficient to proceed in stages, using one of the strategies developed by Hawkins et al. [7]. They refer to the treatments that one wishes to compare as primary comparators. Treatments that have been directly compared with a primary comparator are secondary comparators, and treatments that have been directly compared with a secondary comparator are tertiary comparators, and so on. The order of a comparison is determined by the number of intermediate comparators. Thus, first-order comparisons are direct comparisons, second-order indirect comparisons are based on trials that share a single intermediate comparator, third-order indirect comparisons involve two intermediate comparators, and so on.

Table 1 lists the first five searches for their breadth-first strategy. In the searches that exclude a comparator, one can minimize the burden of searching by excluding the comparator that is likely to produce the largest number of hits (e.g., placebo). Each search in the sequence will locate, in the chosen database(s) (e.g., MEDLINE, EMBASE), all clinical trials that contribute to an indirect comparison of the corresponding order: Search 1, all first-order (direct) comparisons; Search 2, all second-order indirect comparisons; and so on. Through these searches, additional treatments that may not be viewed as comparators or within the scope of the appraisal (e.g., unlicensed treatments, in some instances) may contribute to the evidence network.

The depth-first strategy begins with the same search as the breadth-first strategy, but it does not include the omitted comparator in any subsequent search. Search 2 targets all secondary comparators identified in Search 1, Search 3 targets all tertiary comparators identified in Search 2, and so on. Hawkins et al. [7,8] give a detailed discussion of the searches and resulting comparisons for two second-line treatments of advanced/metastatic non-small-cell lung cancer.

The literature review should also search for any meta-analyses that have already produced direct (or even indirect) comparisons of potentially relevant treatments, to provide empirical validation for the analysis.

## Assumptions

As discussed in Part 1 [1], network meta-analysis relies on the randomization in the RCTs that compared the treatments directly. It also involves a similarity assumption: "Combining studies should only be considered if they are clinically and methodologically similar" [9]. Nevertheless, "no commonly accepted standard [defines] which studies are 'similar enough'" [9]. For network meta-analysis, covariates that act as relative treatment effect modifiers must be similar across trials (or adjusted for using meta-regression). And, when it combines indirect evidence with direct evidence, network meta-analysis adds the assumption of consistency: The indirect evidence must be consistent with the direct evidence.

A meta-analysis for a direct comparison usually requires that the individual studies estimate either a common treatment effect or study-specific treatment effects distributed around a typical value

[10]. The choice between a common effect and a distribution of effects gives rise to fixed-effects and random-effects approaches, respectively. Heterogeneity among studies within a direct comparison is acceptable, as long as their treatment effects share a common typical value, and it may even increase generalizability. On the other hand, heterogeneity between the sets of studies that contribute direct comparisons to an indirect comparison or a network meta-analysis would indicate a lack of similarity.

The discussion of models that follows uses the assumptions of homogeneity, similarity, and consistency as needed. In practice, one must check these assumptions, to the extent possible. "Investigators should base decisions about combining studies on thorough investigations of clinical and methodological diversity as well as variation in effect size" [9]. Agreement is seldom perfect, and both statistical and clinical judgment may be required (e.g., re-examining information in the reports on some trials, calculating direct and indirect estimates separately before proceeding to a network meta-analysis). It may be possible to adjust for differences on study-level characteristics (via meta-regression), but such adjustments are unlikely to overcome substantial disparities among the studies. Interpretations of results should acknowledge this limitation.

## Statistical methods

### Objectives

Objectives of network meta-analysis may include considering all relevant evidence, answering research questions in the absence of direct evidence, improving the precision of estimates by combining direct and indirect evidence, ranking treatments, and assessing the impact of certain components of the evidence network.

The choice of effect measure should be determined by the clinical question and the nature of the data. Common measures of relative effect include odds ratio, risk ratio (or relative risk), mean difference, and hazard ratio. The models described below apply to any measure of relative effect, as long as the necessary quantities (e.g., likelihood and link function) are properly defined.

### Models

We present a sequence of models, starting with ordinary meta-analysis by fixed effects and random effects, to show the natural progression to fixed- and random-effects models for networks and then meta-regression models that allow treatment-by-covariate interactions [11,12]. Some models for networks can accommodate data from multiarm trials, but the presence of such trials adds complexity to the analysis.

The models below relate the underlying outcome to the effects of treatments and covariates on a scale that is appropriate for the particular analysis (e.g., log of odds, change from baseline, or log hazard rate). The probability distribution for the observed outcomes (e.g., binomial, normal) would be specified separately. Analysis based on these models could use either frequentist or Bayesian methods; we briefly describe both.

*Fixed- and random-effects meta-analysis for AB trials.* Equation 1 shows the fixed-effects model for meta-analysis comparing treatment B with treatment A.

$$\eta_{jk} = \begin{cases} \mu_j & k = A \\ \mu_j + d & k = B \end{cases} \tag{1}$$

$\eta_{jk}$ reflects the underlying outcome for treatment $k$ in study $j$, $\mu_j$ represents this outcome for treatment A in study $j$, and $d$ is the effect of treatment B relative to treatment A. In a fixed-effect analysis, $d$ is the same for each study. The random-effects model, equation 2, replaces $d$ with $\delta_j$, the trial-specific effect of

treatment B relative to treatment A, and $d$ becomes the mean of the distribution (usually normal) of random effects, which has variance $\sigma^2$.

$$\eta_{jk} = \begin{cases} \mu_j & k = A \\ \mu_j + \delta_j & k = B \end{cases} \tag{2}$$

$$\delta_j \sim N(d, \sigma^2)$$

*Fixed-effects network meta-analysis.* When the evidence network consists of multiple pairwise comparisons (i.e., AB trials, AC trials, BC trials, and so on), the set of comparators usually varies among studies, complicating the notation. One approach labels the treatments A, B, C, and so on, and uses A for the primary reference treatment in the analysis. In each study it designates one treatment, $b$, as the base treatment. The labels can be assigned to treatments in the network in such a way that the base treatments follow A (i.e., B, C, and so on) and the non-base treatments follow all the base treatments in the alphabet. In the various models, "after" refers to this alphabetical ordering. The general fixed-effects model for network meta-analysis can be specified as follows:

$$\eta_{jk} = \begin{cases} \mu_{jb} & b = A, B, C, & \text{if } k = b \\ \mu_{jb} + d_{bk} = \mu_{jb} + d_{Ak} - d_{Ab} & k = B, C, D, & \text{if } k \text{ is 'after' } b \end{cases} \tag{3}$$

$$d_{AA} = 0$$

$\mu_{jb}$ is the outcome for treatment $b$ in study $j$, and $d_{bk}$ is the fixed effect of treatment $k$ relative to treatment $b$. The $d_{bk}$ are identified by expressing them in terms of effects relative to treatment A: $d_{bk} = d_{Ak} - d_{Ab}$ with $d_{AA} = 0$ (the order of the subscripts on $d_{bk}$ is conventional, but counterintuitive). For the underlying effects, this relation is a statement of consistency: the "direct" effect $d_{bk}$ and the "indirect" effect $d_{Ak} - d_{Ab}$ are equal.

In the simplest indirect treatment comparison, A is the primary reference treatment and also the base treatment for the AB trials and the AC trials. The term "adjusted indirect comparison" has been applied to such analyses, but it is an infelicitous choice, because the comparison involves no adjustment in any of the usual senses. We prefer "anchored indirect comparison"; the indirect comparison of B and C is anchored on A.

*Random-effects network meta-analysis.* As above, the random-effects model replaces $d_{bk}$ with $\delta_{jbk}$, the trial-specific effect of treatment $k$ relative to treatment $b$. These trial-specific effects are drawn from a random-effects distribution: $\delta_{jbk} \sim N(d_{bk}, \sigma^2)$. Again, the $d_{bk}$ are identified by expressing them in terms of the primary reference treatment, A. This model assumes the same random-effect variance $\sigma^2$ for all treatment comparisons, but the constraint can be relaxed. (A fixed-effects model results if $\sigma^2 = 0$.)

$$\eta_{jk} = \begin{cases} \mu_{jb} & b = A, B, C, & \text{if } k = b \\ \mu_{jb} + \delta_{jbk} & k = B, C, D, & \text{if } k \text{ is 'after' } b \end{cases} \tag{4}$$

$$\delta_{jbk} \sim N(d_{bk}, \sigma^2) = N(d_{Ak} - d_{Ab}, \sigma^2)$$

$$d_{AA} = 0$$

*Meta-regression models with treatment-by-covariate interactions.* Meta-regression models include study-level covariates and provide a way to evaluate the extent to which covariates account for heterogeneity of treatment effects. They can also reduce bias and inconsistency between treatment comparisons when covariates are distributed unevenly [13,14]. The covariates enter the model via the mean of the distribution of random effects. The model below uses study-level values of a single covariate, $X_j$, and allows its coefficient, $\beta_{bk}$, to vary among the comparisons [12]. It is a good

idea to center a covariate (e.g., at its overall mean), to make the results more interpretable.

$$n_{jk} = \begin{cases} \mu_{jb} & b = A, B, C, & \text{if } k = b \\ \mu_{jb} + \delta_{jbk} & k = B, C, D, & \text{if } k \text{ is 'after' } b \end{cases}$$
$$\delta_{jbk} \sim N(d_{bk} + \beta_{bk}X_j, \sigma^2) = N(d_{Ak} - d_{Ab} + (\beta_{Ak} - \beta_{Ab})X_j, \sigma^2) \qquad (5)$$
$$d_{AA} = 0, \beta_{AA} = 0$$

Other models can use values of the covariate for the combination of study and treatment. A simplification of the model above uses the same coefficient for all comparisons:

$$n_{jk} = \begin{cases} \mu_{jb} & b = A, B, C, & \text{if } k = b \\ \mu_{jb} + \delta_{jbk} & k = B, C, D, & \text{if } k \text{ is 'after' } b \end{cases}$$
$$\delta_{jbk} \sim \begin{cases} N(d_{bk} + \beta X_j, \sigma^2) = N(d_{Ak} - d_{Ab} + \beta X_j, \sigma^2) & \text{if } b = A \\ N(d_{bk}, \sigma^2) = N(d_{Ak} - d_{Ab}, \sigma^2) & \text{if } b \neq A \end{cases} \qquad (6)$$
$$d_{AA} = 0$$

If a model with a constant $\beta$ is satisfactory, comparisons among treatments (adjusted for the contribution of the covariate) are straightforward, because $d_{Ak} - d_{Ab}$ applies at any value of the covariate (study-level or study-by-treatment-level). In the model with $\beta_{bk}$ the adjustment for the covariate can improve internal validity, but the analyst must choose a value of $X$ at which to make comparisons among treatments. Meta-regression also has the drawback that the relation between the outcome and the covariate in patient-level data can differ, and even be opposite in direction, from the corresponding relation in study-level summaries.

If the network appropriately includes a multiarm trial, omitting it from the analysis may introduce bias. The analysis, then, must take into account the correlation among the effect estimates for the pairs of arms; some methods can do this more easily than others. It is incorrect to analyze the pairwise effects in a multiarm trial as if they came from separate studies. This error is not rare; an example in a Canadian Agency for Drugs and Technologies in Health report shows the input data for the three direct comparisons in a three-arm trial as three separate studies [15]. Salanti et al. [16] illustrate analyses that incorporate correlation among arms.

## Analysis framework: Frequentist versus Bayesian approaches

*Frequentist approach.* The label "frequentist" applies to most of the traditional statistical methods applied in making comparisons, including the weighted means with confidence intervals (based on an assumed normal distribution) in fixed-effects and random-effects meta-analysis and the Mantel-Haenszel estimate (e.g., for an odds ratio) (a fixed-effects procedure). In models such as network meta-analysis and meta-regression, estimation and inference are based on some form of maximum likelihood.

*Bayesian approach.* Bayesian methods combine the likelihood (roughly, the probability of the data as a function of the parameters) with a prior probability distribution (which reflects prior belief about possible values of those parameters) to obtain a posterior probability distribution of the parameters [17]. The posterior probabilities provide a straightforward way to make predictions, and the prior distribution can incorporate various sources of uncertainty. For parameters such as treatment effects, the customary prior distributions are noninformative. The assumption that, before seeing the data, all values of the parameter are equally likely minimizes the influence of the prior distribution on the posterior results. When information on the parameter is available (e.g., from observational studies or from a previous analysis), however, the prior distribution provides a natural way to incorporate it.

For one random-effects network model in which the outcome measure is log odds, the Bayesian analysis has the following components:

likelihood:
$$r_{jk} \sim binomial(p_{jk}, n_{jk})$$
model:
$$logit(p_{jk}) = \begin{cases} \mu_{jb} & b = A, B, C, & \text{if } k = b \\ \mu_{jb} + \delta_{jbk} & k = B, C, D, & \text{if } k \text{ is 'after' } b \end{cases}$$
$$\delta_{jbk} \sim N(d_{bk}, \sigma^2) = N(d_{Ak} - d_{Ab}, \sigma^2) \qquad (7)$$
$$d_{AA} = 0$$
priors:
$$d_{Ak} \sim normal(0, 10^6) \quad k = B, C, D$$
$$\sigma \sim uniform[0, 2]$$

In the likelihood the observed number of events for treatment $k$ in study $j$, $r_{jk}$, has a binomial distribution (independent of other treatments in study $j$ and of other studies) whose event probability is $p_{jk}$, described by the model. The parameters in the distributions of random effects have vague prior distributions: $N(0, 10^6)$ for the $d_{Ak}$ (independently) and Uniform(0, 2) for $\sigma$. These priors are common choices in such models.

*Differences.* For most of the models an analysis could follow either a frequentist approach or a Bayesian approach. In current practice most meta-analyses for direct comparisons use frequentist methods. For the more-complicated models, particularly networks involving mixed treatment comparisons, Bayesian methods have undergone substantially greater development, facilitated by advances in computing that support their computational intensity and the need to monitor convergence to the posterior distribution. Lumley [18] described a maximum-likelihood approach using linear mixed models; his method has been applied in relatively few articles [19–21].

In brief, a frequentist analysis yields point estimates and confidence intervals. The typical Bayesian analysis produces an empirical version of the joint posterior distribution of the parameters, from which one can derive summary measures for individual parameters, such as the posterior mean and a "credible interval" (CrI) (e.g., the endpoints of the 95% CrI are the 2.5 and 97.5 percentiles of the posterior distribution), as well as posterior distributions for functions of parameters (e.g., estimates of the probability that each treatment is best). The Bayesian CrIs reflect the uncertainty in estimating heterogeneity, whereas frequentist random-effects models do not propagate that uncertainty.

Choices of prior distributions are, to some extent, arbitrary, so they are often subjected to sensitivity analysis, which may be especially important for priors on heterogeneity in random-effects models. Lambert et al. [22] discuss sensitivity analysis for exploring the effect of the use of vague priors. On the other hand, some frequentist methods involve approximations and assumptions that are not stated explicitly or verified when the methods are applied. Therefore both insight into the sensitivity of results from a Bayesian analysis to assumptions on priors and transparent reporting of assumptions underlying a frequentist analysis are highly important.

## Model validation

*Evaluation of assumptions.* As mentioned above, assumptions require checking. In assessing similarity, researchers may be able to use statistical information, but they must rely primarily on clinical judgment of whether differences among studies may affect the comparisons of treatments or make some comparisons inappropriate.

Evaluation of homogeneity and consistency (if the network supports both direct and indirect comparisons) should be specified as components of the analysis and should reflect the risks and benefits of combining data for the particular research question.

The discussion that follows sketches the current state of some approaches for examining homogeneity and consistency.

Ordinary meta-analyses (especially by frequentist methods) customarily evaluate heterogeneity of effects, as a basis for choosing between a fixed-effect or a random-effects procedure. Borenstein et al. [23] advise against considering a fixed-effect model as a presumptive choice; they explain that fixed-effect models and random-effects models reflect fundamentally different assumptions about the distribution of the data. Thus, the choice should reflect an understanding of whether the studies share a common effect and the goals of the analysis. These issues are at least as important in a network meta-analysis. When information on heterogeneity within the direct comparisons is available, consideration of it can form a preliminary step in a network meta-analysis, but one should first examine potential effect modifiers, because disparities among studies may preclude analysis of the network. The common measures of heterogeneity in a direct comparison use the studies' estimates, $y_i$ ($i = 1, \ldots, k$), of effect and the estimated variances of those effect estimates, $s_i^2$, to form the weighted mean, $\bar{y}_w = (\sum w_i y_i)/(\sum w_i)$, where $w_i = 1/s_i^2$ ($\bar{y}_w$ is the fixed-effect estimate of the common effect). They then calculate the statistic $Q$,

$$Q = \sum w_i (y_i - \bar{y}_w)^2$$

and either refer it to the chi-squared distribution on $k-1$ degrees of freedom or quantify the heterogeneity in terms of the measure $I^2 = [Q - (k-1)]/Q$ [24]. $I^2$ (usually expressed as a percentage) estimates the proportion of total variation among the effect estimates that is due to heterogeneity: $I^2 < 30\%$ is considered mild heterogeneity, and $I^2 > 50\%$, notable heterogeneity. Deeks et al. [25] discuss strategies for addressing heterogeneity. It is important to examine the effects graphically for the presence of groups and outliers; these numerical measures or tests should have only a secondary role [9,26]. It has long been known that the large-sample approximation for the distribution of $Q$ is not accurate for moderate sample sizes; thus, use of $Q$ for testing homogeneity should be abandoned in favor of more-accurate tests [27].

A departure from consistency arises when the direct and indirect estimates of an effect differ (e.g., the direct estimate of $d_{BC}$ does not equal the indirect estimate obtained from $d_{AC} - d_{AB}$). The treatments involved (and their comparisons) must belong to a loop in the network of evidence. Thus, consistency is a property of loops, rather than of individual comparisons. Researchers must evaluate departures from consistency and determine how to interpret them. Salanti et al. [16] provide much valuable guidance. Most agencies to which the results of a network meta-analysis could be submitted currently require that direct estimates and indirect estimates be calculated separately and shown to be consistent before direct evidence and indirect evidence are combined.

Methods for evaluating consistency have been an active area of research. In a network containing a single loop (and no multiarm trials) Bucher et al. [28] compared the indirect estimate of a treatment effect with the corresponding direct estimate (the resulting test of consistency, however, has shortcomings that may make it unreliable). For networks of two-arm trials that contain loops, Lumley [18] introduced a frequentist model that uses one variance parameter to summarize inconsistency in the network as a whole. Lu and Ades [13] focused on the structure of networks and expanded a hierarchical Bayesian model by adding one parameter for each independent consistency relation. By comparing the models with and without these parameters, one can assess overall inconsistency, and the posterior distributions of the added parameters show the extent of inconsistency in the various loops. A graphical assessment can use the forest plot of Lam and Owen [29] to examine consistency between direct and indirect estimates. In a hierarchical Bayesian setting, Dias et al. [30] extended the approach of Bucher et al. [28] to general networks (but not using indirect evidence from multiarm trials), by deriving a weighted difference between the estimate from the network and the direct estimate. By plotting the posterior densities of the direct, indirect, and network estimates, they show how the direct evidence and the indirect evidence are combined in the network estimate. For each effect that has direct evidence Dias et al. [30] also split the information into direct and indirect information and examine the posterior distribution of the difference between the resulting direct and indirect estimates. They discuss how to handle multiarm trials in this analysis.

*Assessment of model fit.* In frequentist analyses, measures of model fit are similar to those for direct evidence and depend on the particular outcome measure. Bayesian analyses customarily use deviance (a likelihood-based measure)—the lower the residual deviance, the better the fit. For comparing models, the deviance information criterion (DIC) adds a penalty term, equal to the effective number of parameters in the model [31]. If a model fits poorly, graphical techniques can aid more-detailed examination.

*Sensitivity analysis.* Sensitivity analyses should focus on the areas of greatest uncertainty. Potential effect modifiers can be explored by stratifying on variations in study design or population. Comparisons between random-effects and fixed-effects analyses may be appropriate. Bayesian analyses should also explore the influence of choosing different prior distributions.

## Checklist for good research practices

Practices for conducting and reporting systematic reviews and meta-analyses have received extensive discussion since the mid-1980s and have been the subject of guidelines and recommendations, most recently the PRISMA statement [6]. Because network-meta-analysis studies have many features in common with systematic reviews and meta-analyses, we recommend that they follow all applicable parts of the PRISMA checklist. In addition, Table 2 supplements the checklist in Part 1 [1] by highlighting key components of network-meta-analysis studies, areas in which they have distinct (often additional) requirements, and recent developments. We intend this checklist for use in light of ongoing, dynamic research on network meta-analysis. Improved methods and their application will lead to changes in the checklist.

## Illustrative examples

Separate analyses of a portion of the data from two extensive meta-analyses provide illustrations of ITC (both frequentist and Bayesian approaches) and network meta-analysis. This section also discusses available software.

Stettler et al. [32] reported on a collaborative network meta-analysis of outcomes associated with two drug-eluting stents (the paclitaxel-eluting stent [PES] and the sirolimus-eluting stent [SES]) and bare-metal stents (BMS). The literature search yielded 7 RCTs comparing PES with BMS, 15 RCTs comparing SES with BMS, 14 RCTs comparing SES with PES, and 1 RCT comparing all three.

Their analysis of overall mortality and other primary safety endpoints is an instructive application of Bayesian random-effects models for network meta-analysis involving multiple follow-up times [33]. This example focuses on the rate, at 1 year, of target lesion revascularization (TLR), a secondary effectiveness endpoint involving subsequent percutaneous intervention.

The Appendix for this article (found at doi:10.1016/j.jval. 2011.01.011) gives the details of the Bayesian analysis of target lesion revascularization on the log-odds scale: direct meta-analyses of PES versus BMS, SES versus BMS, and PES versus SES; the corresponding separate indirect comparisons; the comparisons from the network meta-analysis; and WinBUGS code and the data.

The forest plot in Figure 1 shows the data from the studies that compared PES and SES, the study-specific odds ratios for PES ver-

**Table 2 – Checklist of good research practices for conducting and reporting network-meta-analysis studies.**

| Checklist item | Recommendation(s) |
|---|---|
| Search strategies | • Follow conventional guidelines for systematic literature searches; be explicit about search terms, literature, and time frames, and avoid use of ad hoc data<br>• Consider iterative search methods to identify higher-order indirect comparisons that do not come up in the initial search focusing on lower-order indirect comparisons |
| Data collection | • Set forth evidence network demonstrating direct and indirect linkages between treatments, based on identified study reports<br>• Follow conventional guidelines for data collection; use a pre-specified protocol and data extraction form<br>• Include sufficient study detail in data extraction to permit assessment of comparability and homogeneity (e.g., patient and study characteristics, comparators, and outcome measures) |
| Statistical analysis plan | • Prepare statistical analysis plan prior to data analysis, but permit modifications during data analysis, if necessary<br>• Provide step-by-step descriptions of all analyses, including explicit statements of all assumptions and procedures for checking them<br>• Describe analytic features specific to network meta-analysis, including comparability and homogeneity, synthesis, sensitivity analysis, subgroup analysis and meta-regression, and special types of outcomes |
| Data analysis | • Follow conventional guidelines for statistical model diagnostics<br>• Evaluate violations of similarity or consistency assumption in evidence network<br>• If similarity or consistency is a problem, consider use of meta-regression models with treatment × covariate interactions to reduce bias |
| Reporting | • Follow PRISMA statement for reporting of meta-analysis<br>• Explicitly state the study research questions (e.g., in Introduction or Objectives section of report)<br>• Provide graphical depiction of evidence network<br>• Indicate software package used in the analysis and provide code (at least in an online appendix) |

sus SES (from the Bayesian analysis), and five estimates of the overall odds ratio: traditional fixed-effects pairwise (using the Mantel-Haenszel method), traditional random-effects pairwise (using the DerSimonian-Laird method), Bayesian direct, Bayesian indirect, and Bayesian network (Fig. 3 of the Appendix, found at doi:10.1016/j.jval.2011.01.011, shows odds ratios for SES versus PES). To facilitate numerical comparisons, Table 3 presents the estimates. The traditional fixed-effects and random-effects estimates and their 95% confidence intervals differ very little: 1.39 (1.17 to 1.66) and 1.38 (1.16 to 1.65). The random-effects interval is no wider, because the estimated heterogeneity is small ($I^2 = 0.74\%$).

To make an anchored indirect estimate of the odds ratio for PES versus SES, using the direct estimates for PES versus BMS and SES versus BMS, it is necessary to omit the three-arm trial (or do a more-complicated calculation that recognizes the contributions of that trial to both direct estimates). The right-hand column of Table 3 gives the estimates without the three-arm trial. The fixed-effects and random-effects indirect estimates are similar, 1.74 (1.28 to 2.36) and 1.70 (1.09 to 2.65) and are considerably higher than their direct counterparts. The confidence interval for the random-effects indirect estimate is considerably wider than that for the fixed-effects estimate, and both are substantially wider than those for the direct estimates. All the confidence intervals are wide enough that further analysis would be required to assess consistency between the indirect estimates and direct estimates.

The three Bayesian estimates, 1.55 (1.17 to 2.05), 1.60 (0.98 to 2.47), and 1.55 (1.22 to 1.96), are similar, and somewhat higher than the traditional fixed-effects and random-effects estimates. The indirect estimate has the widest credible interval. More importantly, the estimate from the Bayesian network meta-analysis has a somewhat narrower credible interval than the Bayesian direct estimate, as a consequence of taking into account all the evidence in the network. We would report that estimate, 1.55 (1.22 to 1.96), as the odds ratio for PES versus SES.

To provide a richer illustration of some aspects of network meta-analysis (e.g., correlations between estimates and probability of a treatment's being best), the Appendix (found at doi: 10.1016/j.jval.2011.01.011) also analyzes data from a network of 112 RCTs that compared (in the aggregate) the acceptability of 12 new-generation antidepressants in the acute-phase treatment of unipolar major depression [34].

### Software

We used WinBUGS for the Bayesian analyses in this example [35]. Other software for Bayesian analysis includes OpenBUGS [36]. Version 9.2 of SAS [37] includes a procedure for Markov chain Monte Carlo, but the examples in the documentation appear not to include applications in meta-analysis. Frequentist approaches have been developed by Lumley [18] in R using linear mixed models and are also feasible in SAS using PROC NLMIXED [38].

## Areas for future research

Research has produced a substantial body of methods for network meta-analysis, but a number of topics would benefit from further investigation. This section discusses eight of them, roughly in order of priority.

### Adjustments to improve the similarity of trials and empirical assessment of their benefit

Patients studied in the various trials may not be comparable. If these differences among trials are treatment-effect modifiers, an ITC is biased [39]. In addition, in a network meta-analysis different types of comparisons may be inconsistent [12]. Because the number of studies is often limited, adjustment by incorporating covariates with "conventional" meta-regression approaches may be unsatisfactory [38–40]. In addition, limited or inconsistent reporting of the study-level covariates (or effects for levels of a possible effect modifier) complicates analysis. Future studies should examine the value of existing methods to enhance comparability of trials, as well as the level of consistency in reporting of study-level covariates.

### Structure and properties of networks

To explore the geometry of treatment networks for four or more interventions, Salanti et al. [2] used two measures from the ecological literature, diversity and co-occurrence. Diversity characterizes the number of interventions and, for a set of networks with the same number of interventions, the frequency distribution of interventions. Co-occurrence measures the appearance of specific pairwise combinations of interventions. These measures allow 1) comparing networks of different sizes within a particular network shape and 2) signaling the presence of potential biases in the assessment or reporting of specific comparisons. It

**Fig. 1 – Forest plot for the PES vs. SES comparison, showing the data from the individual studies and, on the odds-ratio scale, the fixed-effects pairwise (Mantel-Haenszel) and random-effects pairwise (DerSimonian-Laird) estimates and the results from the Bayesian network meta-analysis of direct, indirect, and combined evidence.**

is not known, however, whether these are the best measures to characterize evidence networks, or how they correlate with effect estimates, heterogeneity, similarity, or consistency.

### Methods for verifying the assumption of consistency

As discussed above, a number of approaches, including graphical representations, have been developed to assess consistency in network meta-analysis. Salanti et al. [16] and Dias et al. [30] have discussed the strengths and weaknesses of these approaches. Further research is needed, to improve understanding of these methods and encourage their use. As Salanti et al. [16] point out, a measure for inconsistency analogous to $I^2$ would be a welcome addition.

### Multiple outcomes

Meta-analyses that consider multiple outcomes usually do so in separate analyses. Intuitively, however, because "multiple endpoints are usually correlated, a simultaneous analysis that takes their correlation into account should add efficiency and

accuracy" [41]. Though this approach has received considerable attention in recent years [42–44], it has not yet been extended to network meta-analysis for studies that have analyzed multiple endpoints [45].

Lu et al. [33] illustrated how to combine data recorded at multiple time points; these methods can be extended to estimate treatment effects at multiple time points using the network for each time point and the correlation between multiple observations. This would be beneficial to cost-effectiveness models where transition probabilities vary over time.

Historically meta-analysts have combined studies using a common summary measure (e.g., mean change from baseline) and have excluded studies that presented the same measure in a slightly different way (e.g., mean difference). Methods for combining alternative summary measures have recently been proposed in order to minimize potential selection or reporting bias: Welton et al. [46] presented methods for combining mean change from baseline and mean difference data from different studies, and Woods et al. [47] presented

**Table 3 – Estimates (with 95% confidence interval or credible interval) of the odds ratio for PES vs. SES on target lesion revascularization at 1 y, using data that include and exclude the three-arm trial (BASKET).**

| Approach | All trials | Omitting three-arm trial |
|---|---|---|
| Fixed-effects pairwise (Mantel-Haenszel) | 1.39 (1.17 to 1.66) | 1.45 (1.21 to 1.74) |
| Random-effects pairwise (DerSimonian-Laird) | 1.38 (1.16 to 1.65) | 1.43 (1.19 to 1.73) |
| Bayesian direct | 1.55 (1.17 to 2.05) | 1.51 (1.16 to 1.97) |
| Bayesian indirect | 1.60 (0.98 to 2.47) | 1.80 (1.14 to 2.73) |
| Bayesian network meta-analysis | 1.55 (1.22 to 1.96) | 1.57 (1.26 to 1.96) |
| Fixed-effects anchored indirect | | 1.74 (1.28 to 2.36) |
| PES vs. BMS | | 0.40 (0.32 to 0.49) |
| SES vs. BMS | | 0.23 (0.18 to 0.28) |
| Random-effects anchored indirect | | 1.70 (1.09 to 2.65) |
| PES vs. BMS | | 0.39 (0.28 to 0.54) |
| SES vs. BMS | | 0.23 (0.17 to 0.31) |

BMS, bare-metal stent; PES, paclitaxel-eluting stent; SES, sirolimus-eluting stent.

methods for combining binary mortality data with hazard ratio data from different studies in a single analysis.

Such approaches embrace more studies than separate analyses for each summary measure and also maximize network connectivity. Health technology assessment bodies such as the National Institute for Health and Clinical Excellence may view the use of a single summary measure (and thereby exclusion of certain studies) as potential selection bias and insist on including various summary measures of the same endpoint within a single analysis where these are available [46–48]. Further exploratory work is needed on combining different summary measures of the same endpoint.

### How to handle heterogeneity with small numbers of studies per intervention?

Many network meta-analyses involve too few studies to employ either random effects [8] or meta-regression [12]. The resulting overspecification (i.e., the number of parameters to be estimated exceeds the number of studies) can compel the meta-analyst to use a fixed-effects model when heterogeneity may be present. Cooper et al. [12] proposed alternative random-effects models incorporating covariate adjustment that can mitigate overspecification, depending on the distribution of interactions. In the Bayesian framework, use of informative prior distributions for the heterogeneity parameter would offer a compromise between fixed-effects and random-effects models. These methods need to be further explored.

### Size of the network: evidence space versus decision space

The practitioner may ask, "Is there a direct way of deciding on the size of a network? Is there an optimum? What size is sufficient?" Size involves both the number of studies and the number of treatments. If the number of studies is too small, an analysis cannot use random effects or meta-regression. However, including too many studies can increase the level of inconsistency, potentially resulting in confounding bias. On the other hand, an established treatment may have been included in many studies. The size of the network depends on the therapy and treatment contrast [33], comparators, uncertainty, sample size, homogeneity, quality of information, and exact patient population [39]. Also, it seems that the network size should depend on the expected level of confound-

ing. Though methods can account for inconsistency, and sensitivity analysis can evaluate the robustness of the outcomes derived from a particular network, many issues remain in defining the best network and deciding on the size of the network. Including all relevant data must be balanced against minimizing inconsistency and heterogeneity among studies and populations. Improvements in transparency in the development of networks and in the use of network meta-analysis would help nonspecialists (e.g., health care decision makers) understand the study process, methodology, and findings [39,49]. Sutton et al. [49] suggested that guidance for developing a robust network could be based on expert clinical opinion or statistical/economic considerations of efficiency or cost-effectiveness regarding gains from expanding the network. These issues require further elaboration and possibly a set of standardized criteria.

### Individual patient data in network meta-analysis

Meta-analyses of individual patient data (IPD) are considered the gold standard, as they provide the opportunity to explore differences in effects among subgroups [50,51]. Similarly, network meta-analysis based on IPD can be considered superior. When IPD are available, meta-regression models usually have sufficient power to evaluate heterogeneity and improve consistency. Apart from potentially questionable fit, adjustments based on aggregate-level covariates can produce ecological bias [52]. This problem can be avoided by using IPD, or minimized by using IPD for a subset of studies [53]. The added value of using IPD in network meta-analysis should be further evaluated to develop recommendations on its relevance and practicability.

### Further development of frequentist methods

For network meta-analysis in some more-complex networks of evidence, especially those involving multiarm trials, frequentist methods are less well developed and accessible than their Bayesian counterparts. Further development would benefit users who prefer frequentist methods. Potential approaches include confidence distributions and score-based confidence intervals [54,55]. Also, several widely used methods for meta-analysis rely on approximations or assumptions. For example, the fixed-effect estimate and random-effects estimate of treatment effect (weighted means) assume that the weights based on estimated variances of study-level effects are close enough to the weights based on true variances, and that the estimated variances are uncorrelated with the estimated effects. The fixed-effect and random-effects methods are often unsatisfactory, especially when the sample sizes of some of the individual studies are modest [56–59]. A thorough review of the empirical evidence is needed.

## Conclusion

This article, the second part of the report from the Task Force, sets out general best-practice guidelines for practitioners who are interested in performing network meta-analyses. The underpinning statistical methods are presented and supported by examples that suggest ways of presenting results to nonspecialized audiences. The techniques are not always applicable and may be subject to the biases and limitations discussed in this report. Failure of the assumptions of similarity and consistency may render results questionable. Where the techniques are applicable, care and transparency should be employed, and we encourage adherence to our checklist. Standardization of methods would enhance the overall credibility and applicability of indirect treatment comparisons and network meta-analysis. Finally, ongoing research in many areas should lead to periodic revisions of the recommendations.

## Supplemental Material

Supplemental material accompanying this article can be found in the online version as a hyperlink at doi:10.1016/j.jval.2011.01.011 at www.valueinhealthjournal.com/issues (select volume, issue, and article).

## REFERENCES

[1] Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons & network meta-analysis for health care decision-making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011;14:417–28.

[2] Salanti G, Kavvoura FK, Ioannidis JP. Exploring the geometry of treatment networks. Ann Intern Med 2008;148:544–53.

[3] Sutton AJ, Abrams KR, Jones DR, et al. Methods for Meta-Analysis in Medical Research. Chichester, UK: John Wiley & Sons, Ltd., 2000.

[4] Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons, Ltd., 2008.

[5] Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. Chichester, UK: John Wiley & Sons, Ltd., 2009.

[6] Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264–9.

[7] Hawkins N, Scott DA, Woods B. How far do you go? Efficient searching for indirect evidence. Med Decis Making 2009;29:273–81.

[8] Hawkins N, Scott DA, Woods BS, Thatcher, N. No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data. Value Health 2009;12:996–1003.

[9] Fu R, Gartlehner G, Grant M, et al. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. [posted October 2010]. Available from: http://effectivehealthcare.ahrq.gov/. [Accessed November 20, 2010].

[10] Song F, Loke YK, Walsh T, et al. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 2009;338:b1147.

[11] Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105–24.

[12] Cooper NJ, Sutton AJ, Morris D, et al. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med 2009;28:1861–81.

[13] Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc 2006;101:447–59.

[14] Thompson SG, Smith TC, Sharp SJ. Investigating underlying risk as a source of heterogeneity in meta-analysis. Stat Med 1997;16:2741–58.

[15] Wells GA, Sultan SA, Chen L, et al. Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health, 2009.

[16] Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Stat Methods Med Res 2008;17:279–301.

[17] Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res 2001;10:277–303.

[18] Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002;21:2313–24.

[19] van der Valk R, Webers CA, Lumley T, et al. A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. J Clin Epidemiol 2009;62:1279–83.

[20] Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201–7.

[21] Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289:2534–44.

[22] Lambert PC, Sutton AJ, Burton PR, et al. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med 2005;24:2401–28.

[23] Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synthesis Methods 2010;1:97–111.

[24] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58.

[25] Deeks JJ, Higgins JPT, Altman DG. Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, eds., Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons, Ltd., 2008.

[26] Rücker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on $I^2$ in assessing heterogeneity may mislead. BMC Med Res Methodol 2008;8:79.

[27] Kulinskaya E, Dollinger MB, Bjørkestøl K. Testing for homogeneity in meta-analysis I. The one-parameter case: standardized mean difference. Biometrics 2011;67:203–12.

[28] Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683–91.

[29] Lam SKH, Owen A. Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials. BMJ 2007;335:925.

[30] Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010;29:932–44.

[31] Spiegelhalter DJ, Best NG, Carlin BP. Bayesian measures of model complexity and fit. J R Stat Soc Series B Stat Methodol 2002;64:583–616.

[32] Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937–48.

[33] Lu G, Ades AE, Sutton AJ, et al. Meta-analysis of mixed treatment comparisons at multiple follow-up times. Stat Med 2007;26:3681–99.

[34] Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746–58.

[35] Spiegelhalter DJ, Thomas A, Best NG, Lunn D. WinBUGS User Manual, Version 1.4. Cambridge, UK: MRC Biostatistics Unit, 2002.

[36] OpenBUGS. Available from: www.openbugs.info. [Accessed December 6, 2010].

[37] SAS Institute Inc. SAS/STAT User's Guide, version 9.2. Cary, NC: SAS Institute Inc., 2008.

[38] Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005;9(26).

[39] Jansen JP, Crawford B, Bergman G, Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 2008;11:956–64.

[40] Berlin JA, Santanna J, Schmid CH, et al. Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Stat Med 2002;21:371–87.

[41] Berkey CS, Hoaglin DC, Mosteller F, Colditz GA. A random-effects regression model for meta-analysis. Stat Med 1995;14:395–411.

[42] van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 2002;21:589–624.

[43] Nam I-S, Mengersen K, Garthwaite P. Multivariate meta-analysis. Stat Med 2003;22:2309–33.

[44] Riley RD, Abrams KR, Lambert PC, et al. An evaluation of bivariate random-effects meta-analysis for the joint synthesis of two correlated outcomes. Stat Med 2007;26:78–97.

[45] Welton NJ, Caldwell DM, Adamopoulos E, Vedhara K. Mixed treatment comparison meta-analysis of complex interventions: psychological interventions in coronary heart disease. Am J Epidemiol 2009;169:1158–65.

[46] Welton NJ, Cooper NJ, Ades AE, et al. Mixed treatment comparison with multiple outcomes reported inconsistently across trials: evaluation of antivirals for treatment of influenza A and B. Stat Med 2008;27:5620–39.

[47] Woods BS, Hawkins N, Scott DA. Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. BMC Med Res Methodol 2010;10:54.

[48] Burch J, Paulden M, Conti S, et al. Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation. Health Technol Assess 2009;13(58).

[49] Sutton A, Ades AE, Cooper N, Abrams K. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 2008;26:753–67.

[50] Stewart LA, Clarke MJ. Practical methodology of meta-analyses (overviews) using updated individual patient data. Stat Med 1995;14:2057–79.

[51] Sutton AJ, Higgins JPT. Recent developments in meta-analysis. Stat Med 2008;27:625–50.

[52] Greenland S, Morgenstern H. Ecological bias, confounding, and effect modification. Int J Epidemiol 1989;18:269–74.

[53] Lambert PC, Sutton AJ, Abrams KR, Jones DR. A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. J Clin Epidemiol 2002;55:86–94.

[54] Xie M, Singh K, Strawderman WE. Confidence distributions and a unifying framework for meta-analysis. J Am Stat Assoc 2011;106:320–33.

[55] Agresti A. Score and pseudo-score confidence intervals for categorical data analysis. Stat Biopharm Res In press.

[56] Brockwell SE, Gordon IR. A comparison of statistical methods for meta-analysis. Stat Med 2001;20:825–40.

[57] Sánchez-Meca J, Marín-Martínez F. Confidence intervals for the overall effect size in random-effects meta-analysis. Psychol Methods 2008;13:31–48.

[58] Jackson D. The significance level of the standard test for a treatment effect in meta-analysis. Stat Biopharm Res 2009;1:92–100.

[59] Shuster JJ. Empirical vs natural weighting in random effects meta-analysis. Stat Med 2010;29:1259–65; commentary and reply, 1266–81.